Page last updated: 2024-12-05

repirinast

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Repirinast is a potent and selective inhibitor of phosphodiesterase type 4 (PDE4). PDE4 is an enzyme that breaks down cyclic adenosine monophosphate (cAMP), a second messenger that plays a role in inflammation, immune responses, and other cellular processes. Repirinast has been shown to have anti-inflammatory and immunomodulatory effects in a variety of preclinical models. It is being investigated for the treatment of inflammatory bowel disease, rheumatoid arthritis, asthma, and other inflammatory conditions. Repirinast is orally active and has a good safety profile. '

repirinast: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5050
CHEMBL ID2105300
CHEBI ID32092
SCHEMBL ID29997
MeSH IDM0139568

Synonyms (40)

Synonym
AC-5020
repirinast
romet
my-5116
repirinast [usan:inn:jan]
repirinastum [inn-latin]
brn 4267921
4h-pyrano(3,2-c)quinoline-2-carboxylic acid, 5,6-dihydro-7,8-dimethyl-4,5-dioxo-, isopentyl ester
isopentyl 5,6-dihydro-7,8-dimethyl-4,5-dioxo-4h-pyrano(3,2-c)quinoline-2-carboxylate
4h-pyrano(3,2-c)quinoline-2-carboxylic acid, 5,6-dihydro-7,8-dimethyl-4,5-dioxo-, 3-methylbutyl ester
isoamyl 5,6-dihydro-7,8-dimethyl-4,5-dioxo-4h-pyrano(3,2-c)quinoline-2-carboxylate
repirinast (jan/usan/inn)
D01890
romet (tn)
73080-51-0
3-methylbutyl 7,8-dimethyl-4,5-dioxo-6h-pyrano[3,2-c]quinoline-2-carboxylate
isopentyl 7,8-dimethyl-4,5-dioxo-5,6-dihydro-4h-pyrano[3,2-c]quinoline-2-carboxylate
A837709
4k8ka8b61g ,
repirinastum
unii-4k8ka8b61g
CHEMBL2105300
AKOS016014130
FT-0630818
repirinast [mi]
repirinast [mart.]
repirinast [jan]
repirinast [inn]
repirinast [who-dd]
repirinast [usan]
SCHEMBL29997
DTXSID10223349
CHEBI:32092
BCP16315
3-methylbutyl 5-hydroxy-7,8-dimethyl-4-oxopyrano[3,2-c]quinoline-2-carboxylate
Q7314016
EX-A3508
my5116
CS-0031286
HY-109544

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" There was no significant difference in theophylline half-life before treatment (7."( [The influence of repirinast, an anti-allergic drug, on theophylline pharmacokinetics in patients with bronchial asthma].
Dohi, Y; Houya, I; Kiuchi, H; Nagata, M; Sakamoto, Y; Tabe, K; Yamamoto, K, 1991
)
0.62
"A possible pharmacokinetic interaction between theophylline and repirinast has been investigated in asthmatic patients."( Lack of effect of repirinast on the pharmacokinetics of theophylline in asthmatic patients.
Apichartpichean, R; Hasegawa, T; Horiuchi, T; Kuzuya, T; Nadai, M; Ogura, Y; Takagi, K, 1989
)
0.85

Dosage Studied

ExcerptRelevanceReference
" MY-1250 had no effect on the norepinephrine-induced dose-response curve in isolated rat aorta."( [Cardiovascular effects of MY-5116 and MY-1250].
Hanazuka, M; Hara, Y; Horii, D; Nishi, H, 1986
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
organic molecular entityAny molecular entity that contains carbon.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (23)

TimeframeStudies, This Drug (%)All Drugs %
pre-199010 (43.48)18.7374
1990's12 (52.17)18.2507
2000's1 (4.35)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 21.53

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index21.53 (24.57)
Research Supply Index3.26 (2.92)
Research Growth Index4.20 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (21.53)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (8.70%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (4.35%)4.05%
Observational0 (0.00%)0.25%
Other20 (86.96%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]